1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,210 | 1,250 | 07:41 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | NanoViricides to Present at the Life Science Executive Partnering Congress in Boston on September 17, 2025 | 622 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs... ► Artikel lesen | |
| 18.08. | NanoViricides: A Drug that Could Reduce Metastatic Cancer Resurgence due to Its Anti-Inflammatory Effects in Viral Infections is in Clinical Trials | 442 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / August 18, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 30.07. | Measles Cases Increasing Worldwide, Need the New NV-387 Broad-Spectrum Antiviral to Combat, Says NanoViricides | 716 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 30, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 23.07. | NanoViricides Discusses the Multi-Billion-Dollar Potential of Its Broad-Spectrum Drug NV-387; Its Effectiveness Against Influenza, Coronaviruses, RSV, MPox and Now Measles Expected to Drive Value | 753 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / July 23, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 21.07. | Measles Now Has a Drug - NV-387 Broad-Spectrum Antiviral Successful in Animal Studies, says NanoViricides | 813 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 21, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.: NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of... ► Artikel lesen | |
| 16.07. | WHO Extended Global Emergency Status of MPox Epidemic - Development of Treatment for MPox with NV-387 is Timely, Says NanoViricides | 774 | ACCESS Newswire | SHELTON, CONNECTICUT / ACCESS Newswire / July 16, 2025 / NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development... ► Artikel lesen | |
| 14.07. | Adaptive Clinical Protocol Design for Phase II MPox Clade I Treatment with a Novel Broad-Spectrum Drug NV-387 is Almost Complete, Reports NanoViricides | 878 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| NANOVIRICIDES Aktie jetzt für 0€ handeln | |||||
| 01.07. | NanoViricides: There is a Strong Business Case for Phase II Clinical Program for Treatment of MPox Infection Using NV-387, an Industry-Leading Broad-Spectrum Antiviral Drug Candidate | 648 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / July 1, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC ) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 18.06. | With Rising Variants of COVID and Bird Flu, the Single Broad-Spectrum Antiviral NV-387 Would be the Best Partner for Preparedness, Says NanoViricides' Dr. Diwan | 648 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 18, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.: NNVC ) (the "Company"), asserts that with new rising variants of COVID and Bird Flu, the... ► Artikel lesen | |
| 04.06. | NanoViricides Measles Drug Development Animal Study is Imminent | 713 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / June 4, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a clinical stage, leading global pioneer in the development of broad-spectrum... ► Artikel lesen | |
| 28.05. | NanoViricides to Present at the BIO International Convention in Boston on Monday, June 16, 2025 | 1.035 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 28, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus... ► Artikel lesen | |
| 22.05. | The New Rational FDA COVID Vaccine Policy is Long Overdue, Says NanoViricides' Dr. Diwan | 898 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 22, 2025 / Dr. Anil Diwan, President of NanoViricides, Inc. (NYSE Amer.:NNVC ) (the "Company"), comments on the new COVID Vaccine policy adopted by the US FDA.The... ► Artikel lesen | |
| 16.05. | NanoViricides GAAP EPS of -$0.14 | 7 | Seeking Alpha | ||
| 16.05. | NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat Measles Outbreaks, and to Tackle Bird Flu | 957 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 16, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the quarter ending March 31, 2025... ► Artikel lesen | |
| 15.05. | NANOVIRICIDES, INC. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 14.05. | NanoViricides: Measles Cases Are Increasing Globally; MPox Continues to Be a Threat - Broad-Spectrum Antiviral Drug Could Be the Solution | 946 | ACCESS Newswire | NanoViricides Explains Its Drug Strategy for Combating Viral Infections and Pandemics SHELTON, CT / ACCESS Newswire / May 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC)... ► Artikel lesen | |
| 08.05. | NanoViricides: Broad-Spectrum Antiviral Drug NV-387 Cleared for Phase II Clinical Trial Application by the National Ethics Committee of the Democratic Republic of Congo | 951 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / May 8, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company") today reported that it has received approval from the National Ethics Committee for Health (CNES)... ► Artikel lesen | |
| 05.05. | D.Boral Capital: NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC | 940 | Newsfile | Shelton, Connecticut--(Newsfile Corp. - May 5, 2025) - NanoViricides, Inc. (NYSE American: NNVC), (the "Company"), a leading clinical stage global pioneer in the development of broad-spectrum antivirals... ► Artikel lesen | |
| 29.04. | Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It | 828 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 29, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals... ► Artikel lesen | |
| 14.04. | Measles Outbreak Expands Begging for a Drug to Treat the Infection - NanoViricides Declares it is Ready to Fight the Outbreak | 1.063 | ACCESS Newswire | SHELTON, CT / ACCESS Newswire / April 14, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the "Company"), and a leading global pioneer in the development of broad-spectrum antivirals... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FORMYCON | 21,700 | +0,70 % | Aktie von Formycon büßt 2,70 Prozent ein (21,60 €) | Die Formycon-Aktie notiert heute leichter. Das Wertpapier kostete zuletzt 21,60 Euro. Für Inhaber von Formycon ist der heutige Handelstag bisher nicht sonderlich gut verlaufen. Die Aktie weist derzeit... ► Artikel lesen | |
| ONTO INNOVATION | 103,00 | +0,98 % | EQS-Media: LPKF Laser & Electronics SE: Onto Innovation und LPKF treiben gemeinsam die Massenproduktion von Glassubstraten für Halbleiter voran | EQS-Media / 02.04.2025 / 09:00 CET/CEST
Onto Innovation und LPKF treiben gemeinsam die Massenproduktion von Glassubstraten für Halbleiter voran
LPKF schließt sich dem Packaging Applications... ► Artikel lesen | |
| SOLESENCE | 3,280 | -4,37 % | Solésence, Inc.: Solésence Reports Second Quarter 2025 Financial Results | ROMEOVILLE, Ill., July 31, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced... ► Artikel lesen | |
| GAUZY | 5,540 | +0,36 % | Gauzy: Michael Donnelly tritt aus persönlichen Gründen aus dem Verwaltungsrat zurück | ||
| KOPIN | 2,016 | +1,56 % | Canaccord Genuity raises Kopin stock price target to $3 on growth prospects | ||
| VEECO INSTRUMENTS | 22,400 | -0,88 % | Benchmark Reaffirms 'Buy' Rating on Veeco Instruments Inc. (VECO); Sets $28 PT | ||
| GOMSPACE | 1,158 | +4,70 % | GomSpace Group AB receives observation status | On August 29, 2025, The Hargreaves Family No. 14 Settlement disclosed a mandatory public offer to the other shareholders in GomSpace Group AB.
The rules of Nasdaq First North Growth Market state... ► Artikel lesen | |
| OBDUCAT | 0,030 | +50,00 % | NGM MARKET NOTICE: #25-43 Information regarding the last day of trading in paid subscribed shares issued by Obducat AB | ||
| ACACIA RESEARCH | 2,780 | +1,46 % | Acacia Research und Partner entwickeln eine mit Bitcoin gesicherte Gewerbedarlehensstrategie | ||
| NVE | 56,00 | 0,00 % | Dividendenbekanntmachungen (04.08.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) AMERIPRISE FINANCIAL INC US03076C1062 1,6 USD 1,3806 EUR AMERISERV FINANCIAL INC US03074A1025 0,03 USD 0,0258 EUR ATLANTIC UNION... ► Artikel lesen | |
| ADVANCE ZINCTEK | 0,452 | 0,00 % | ADVANCE ZINCTEK LIMITED: Response to Rumours Re CHOICE Sunscreen Test Findings | ||
| LAMPETIA | 0,102 | 0,00 % | EQS-News: LEHNER INVESTMENTS AG: Jahresabschluss 2024 mit positivem Ergebnis | EQS-News: LEHNER INVESTMENTS AG
/ Schlagwort(e): Jahresergebnis
LEHNER INVESTMENTS AG: Jahresabschluss 2024 mit positivem Ergebnis
30.06.2025 / 16:18 CET/CEST
Für den... ► Artikel lesen | |
| NANOFOCUS | 1,400 | 0,00 % | NanoFocus: Hauptaktionär plant Squeeze-out | Die Carl Mahr Holding GmbH hat ein offizielles Verlangen auf Durchführung eines aktienrechtlichen Squeeze-outs bei der NanoFocus AG übermittelt. Demnach soll die Hauptversammlung einen Beschluss fassen... ► Artikel lesen | |
| RIBER | 3,340 | +3,25 % | New milestone for RIBER in silicon photonics with a ROSIE order in the United States | New milestone for RIBER in silicon photonics with a ROSIE order in the United States Bezons (France), 8 September 2025 - 8:00 am - RIBER, a global market leader in molecular beam epitaxy (MBE) equipment... ► Artikel lesen | |
| REGION GROUP | 1,363 | 0,00 % | REGION GROUP: Change of Director's Interest Notice |
NANOVIRICIDES INC gehört der Branche Nanotechnologie an. Die relative Kursveränderung beträgt aktuell +3,48 % bei einem Aktienkurs von 1,190 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NANOVIRICIDES INC finden Sie auf Wallstreet Online.